NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Monday reported a first-quarter loss of $96.8 million, after reporting a profit in the same period a year earlier.
The Novato, California-based company said it had a loss of $1.82 per share.
The results did not meet Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of $1.73 per share.
The biotechnology company posted revenue of $18.2 million in the period, which also fell short of Street forecasts. Eight analysts surveyed by Zacks expected $19.3 million.
Ultragenyx shares have climbed 55% since the beginning of the year. In the final minutes of trading on Monday, shares hit $67.24, a rise of 23% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RARE at https://www.zacks.com/ap/RARE